“The regulation of emotion recognition in the EU AI Act shows a dangerous reversal of the precautionary principle. Despite the premise in recital 44 – ‘there are serious concerns about the scientific basis of AI systems aiming to identify or infer emotions […]’ – emotion recognition is prohibited only in very delimited cases. This policy choice is one of many indicators of the gradual weakening, even in the European Union, of the pillars of a democratic society”.
“Così muore la libertà. Tra scroscianti applausi in nome di una società più salda e sicura”
La disciplina del riconoscimento emozionale nell’AI Act dell’Unione Europea segnala un pericoloso ribaltamento del principio di precauzione. Nonostante la premessa contenuta nel considerando 44 – “sussistono serie preoccupazioni in merito alla base scientifica dei sistemi di IA volti a identificare o inferire emozioni” -, il riconosciemento emozionale è vietato solo in fattispecie molto delimitate. Tale scelta politica costituisce una delle tante spie del progressivo indeblimento, anche nell’Unione Eurpea, dei pilastri di una società democratica.
“Clinical and research activities produce enormous amounts of data. These data represent an invaluable treasure from multiple points of views: scientific interests in creating new medicines and pursuing progress and innovation in the health domain, the necessity to verify the studies carried out, the purely commercial approach on protecting the effort to obtain a marketing authorization (i.e drug control regulation by reference agencies), and the public interest in access and disclosure. Access to this information is often severely limited (if not completely hindered) by forms of exclusive rights (Intellectual Property Rights, Sui generis protection such as the so-called data exclusivity, etc.). The regulations regarding the protection of personal data (indirectly) contribute too in making sharing processes more complex. On the contrary, Open Science, FAIR (Findability, Accessibility, Interoperability, and Reuse) principles, transparency and flexibility needs and the creation of public databases on clinical trials and health data push forward the implementation of accessible or open data.
The Conference aims to investigate the interplay between the several legal tools involved in this phenomenon and open science for health and clinical trial data from multiple perspectives, focusing on EU law but with a comparative approach and methodology (i.e. USA, Canada, Israel, South-Africa) that takes into account the complex regulatory framework”
IX convegno annuale dell’AISA, Scuola Normale Superiore, Pisa, 7-8 novembre 2024
Il IX convegno annuale dell’AISA, organizzato con la Scuola Normale Superiore, si svolgerà a Pisa il 7 e l’8 novembre 2024 e sarà dedicato a Il valore della ricerca: scienza aperta fra pubblicità e pubblicazione / The value of research: open science between publicness and publication e sarà introdotto, la mattina del 7 novembre, da una tavola rotonda dedicata allo stato della scienza aperta in Italia.
The Law and Technology Consortium (LawTech Consortium/LTC) is an international and informal consortium of research centers and institutions seeking to establish a collaborative network between members and share scientific knowledge and expertise in the field of law and technology.
Coordinators
The LTC is coordinated by Prof. Roberto Caso (University of Trento, Italy, Faculty of Law, LawTech research Group), Prof. Pierre-Emmanuel Moyse (McGill University – Faculty of Law), Prof. Gideon Parchomovsky (University of Pennsylvania, United States, School of Law; Hebrew University of Jerusalem, Israel, Faculty of Law), and Prof. Christopher Yoo (University of Pennsylvania, United States).